RELEASE DATE: July 1, 2020
EXPIRATION DATE: June 30, 2021
This CME/CE program will highlight novel BTK (Bruton’s tyrosine kinase) inhibitors and their effects on adaptive and innate immunity in multiple sclerosis (MS). The expert faculty, led by Dr. Fred D. Lublin, will review BTK inhibitor science as a therapeutic target to reduce neuroinflammation and damage to the CNS in patients with MS. The faculty will analyze the safety and efficacy of ongoing BTK inhibitor clinical trials to improve the management of patients with relapsing and progressive forms of multiple sclerosis. Treatment strategies for the application of newer disease-modifying therapeutics to optimize outcomes in patients with MS will be discussed. Upon completion of this activity, clinicians will gain further insight into novel BTK inhibitors and their effect on patients with multiple sclerosis.
Neurologists, nurse practitioners, nurses, physician assistants, pharmacists, and other healthcare professionals involved in the management of patients with multiple sclerosis
- Why We Need New Approaches to Treating MS – Fred D. Lublin, MD
- The Science of BTK Inhibitors: Adaptive and Innate Immunity – Benjamin M. Greenberg, MD, MHS
- A Clinical Trial Review and Analysis on the Safety and Efficacy of Novel BTK Inhibitors – Mark S. Freedman, MD
- Faculty Panel Discussion: Treatment Strategies for the Application of BTK-Inhibitor Therapeutics to Optimize MS Patient Outcomes & Audience Q&A – Fred D. Lublin, MD & Faculty
- Understand BTK inhibitor science as a therapeutic target to reduce neuroinflammation and damage to the CNS in patients with MS.
- Analyze ongoing clinical trials for the efficacy and safety of novel BTK inhibitors to improve the management of patients with relapsing and progressive forms of MS.
- Discuss treatment strategies for the application of newer disease-modifying therapeutics to optimize outcomes in patients with MS.
Fred D. Lublin, MD (Course Chair)
Saunders Family Professor of Neurology
Director, Corinne Goldsmith Dickinson Center for MS
Icahn School of Medicine at Mount Sinai
New York, New York
Mark S. Freedman, MD
Professor of Medicine
University of Ottawa
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada
Benjamin M. Greenberg, MD, MHS
Vice Chair of Translational Research
Department of Neurology and Neurotherapeutics
Director, Neuroimmunology Programs
UT Southwestern Medical Center
Children’s Medical Center
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
Fred D. Lublin, MD
Consultant/Advisor: Acorda Therapeutics, Inc.; Actelion Pharmaceuticals Ltd./Janssen Pharmaceutica; Apitope; Atara Biotherapeutics; Avotres Inc.; Biogen, Inc.; Brainstorm Cell Therapeutics; EMD Serono, Inc.; GW Pharma; Immunic Therapeutics; Innate Immunotherapeutics; Jazz Pharmaceuticals; Mapi Pharma; MedDay Pharma; MedImmune LLC/Viela Bio; Mylan Pharmaceuticals; Novartis Pharmaceuticals Corporation; Orion Biotechnology; Polpharma Biologics; Population Council; Receptos Inc./Celgene Corporation; Roche Pharma/Genentech Inc.; Sanofi/Genzyme; Teva Pharmaceuticals; TG Therapeutics
Grant/Research Support: Actelion Pharamaceuticals Ltd.; Biogen, Inc.; Brainstorm Cell Therapeutics; Novartis Pharmaceuticals Corporation; Sanofi
Speaker’s Bureau: Sanofi Genzyme
Mark S. Freedman, MD
Consultant/Advisor: Actelion Pharmaceuticals, Ltd. (Janssen Pharmaceutica); Alexion Phramaceuticals, Inc.; Atara Biotherapeutics; Bayer Healthcare Pharmaceuticals LLC; Biogen, Inc.; Celgene Corporation (Bristol Myers Squibb); Clene Nanomedicine, Inc.; GRI Bio, Inc.; Hoffman La-Roche AG; Magenta Therapeutics; Merck Serono; MedDay Pharma; Novartis Pharmaceuticals Corporation; Sanofi Genzyme; Teva Pharmaceuticals Canada Innovation
Grant/Research Support: EMD Inc. (Canada); Hoffman-La Roche AG; Sanofi Genzyme Canada
Speaker’s Bureau: EMD Serono; Sanofi-Genzyme
Receipt of honoraria or consultation fees: Actelion Pharmaceuticals, Ltd. (Janssen Pharamaceutica); Alexion Pharmaceuticals, Inc.; Biogen, Inc; Celgene Corporation (Bristol Meyers Squibb); EMD Inc.; Sanofi Genzyme; Hoffman La-Roche AG; Merck Serono; Novartis Pharmaceuticals Corporation; Teva Pharmaceuticals Canada Innovation
Benjamin M. Greenberg, MD, MHS
Consultant/Advisor: Abcam; Alexion Pharmaceuticals; Axon Advisors LLC; EMD Serono, Inc.; Greenwich Biosciences, Inc.; Hoffman La-Roche AG; Novartis Pharmaceuticals Corporation; Rubin/Anders; Viela Bio.
Grant/Research Support: Clene Nanomedicine; Guthy Jackson Charitable Foundation; NIH; NMSS; PCORI; TMA
Planners and Peer Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Nicole Brestowski and Chelsey Benedek hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.